Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase i clinical trial for glioblastoma

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 2, 2010, Pages 204-213

  Muhammad, A K M G ^a   Puntel, M ^a   Candolfi, M ^a   Salem, A ^a   Yagiz, K ^a   Farrokhi, C ^a   Kroeger, K M ^a   Xiong, W ^a   Curtin, J F ^a   Liu, C ^a   Lawrence, K ^a   Bondale, N S ^a   Lerner, J ^a   Baker, G J ^a   Foulad, D ^a   Pechnick, R N ^a,b,c   Palmer, D ^d   Ng, P ^d   Lowenstein, P R ^a,b,c   Castro, M G ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLT3 LIGAND; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; IMMUNOSTIMULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSGENE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BEHAVIOR, ANIMAL; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE DOSAGE; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS; NEOPLASM TRANSPLANTATION; RATS; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TRANSGENES;

EID: 77954888233     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.260     Document Type: Article

References (47)

1. Central Nervous system tumors (discussion). Central Nervous system tumors track. AsCO Annual Meeting, Orlando, FL, 29 May-2 June, 2009.
2. Wen, P.Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507 (2008).
3. Grossman, S.A. et al. Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United states. AsCO Annual Meeting, Orlando, FL, 29 May-2 June, 2009.
4. Stupp, R. et al.; European Organisation for Research and treatment of Cancer Brain tumor and Radiotherapy groups. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11, 165-180 (2006).
5. Stupp, R., Hottinger, A.F., van den Bent, M.J., Dietrich, P.Y. & Brandes, A.A. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. Ann. Oncol. 19 (suppl. 7), vii209-vii216 (2008).
6. Stupp, R. et al.; European Organisation for Research and treatment of Cancer Brain tumor and Radiotherapy groups. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
7. Curtin, J.F. et al. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr. Top. Med. Chem. 5, 1151-1170 (2005).
8. Curtin, J.F. et al. HMgB1 mediates endogenous tLR2 activation and brain tumor regression. PLoS Med. 6, e10 (2009).
9. Candolf, M. et al. Release of HMgB1 in response to proapoptotic glioma killing strategies: efcacy and neurotoxicity. Clin. Cancer Res. 15, 4401-4414 (2009).
10. Candolf, M. et al. gene therapy for brain cancer: combination therapies provide enhanced efcacy and safety. Curr. Gene Ther. 9, 409-421 (2009).
11. Wei, J. et al. topotecan enhances immune clearance of gliomas. Cancer Immunol. Immunother. 58, 259-270 (2009)
12. Ali, S. et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 65, 7194-7204 (2005).
13. Muhammad, A.K.M.G. et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin. Cancer Res. 15, 6113-6127 (2009).
14. King, G.D. et al. Flt3L in combination with HsV1-tK-mediated gene therapy reverses brain tumor-induced behavioral defcits. Mol. Ther. 16 682-690 (2008).
15. King, G.D. et al. Flt3L and tK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-oncology 10 19-31 (2008).
16. Pulkkanen, K.J. & Yla-Herttuala, S. gene therapy for malignant glioma: current clinical status. Mol. Ther. 12, 585-598 (2005).
17. Immonen, A. et al. AdvHsV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10, 967-972 (2004).
18. Sathornsumetee, S. & Rich, J.N. Designer therapies for glioblastoma multiforme. Ann. N. Y. Acad. Sci. 1142, 108-132 (2008).
19. Ark-therapeutics. Cerepro® Phase III trial update: Analyses strengthen as more patients reach endpoint. http://investors.arktherapeutics. com/servlet/HsPublic?context=ir.access&ir-option=RNs-NEWs&item= 126418067393456&ir-client-id=4553&transform=newsitem-new
20. 2009 Ark-therapeutics. Cerepro® Phase III trial update: Analyses strengthen as more patients reach endpoint. (2009).
21. Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R. & Wilson, J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583 (1999)
22. Thomas, C.E., schiedner, G., Kochanek, S., Castro, M.G. & Löwenstein, P.R. Peripheral infection with adenovirus causes unexpected long-term brain infammation in animals injected intracranially with frst-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A. 97, 7482-7487 (2000).
23. Barcia, C. et al. In vivo mature immunological synapses forming sMACs mediate clearance of virally infected astrocytes from the brain. J. Exp. Med. 203, 2095-2107 (2006).
24. King, G.D. et al. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J. Virol. 82 4680-4684 (2008).
25. Morral, N. et al. Administration of helper-dependent adenoviral vectors and sequential delivery of diferent vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U.S.A. 96, 12816-12821 (1999).
26. Parks, R.J., Chen, L., Anton, M., sankar, U., Rudnicki, M.A. & graham, F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570 (1996).
27. O'Neal, W.K. et al. toxicity associated with repeated administration of frst-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med. 6, 179-195 (2000).
28. Maione, D. et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. U.S.A. 98, 5986-5991 (2001)
29. Barcia, C.et al. sustained, one year expression from high-capacity helper-dependent adenoviral vectors delivered to the brain of animals with a pre-existing systemic anti-adenoviral immune response: implications for clinical trials. Mol. Ther. 15, 2154-2163 (2007).
30. Candolf, M. et al. Efective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol. Ther. 14, 371-381 (2006).
31. Candolf, M. et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-oncology 9, 245-258 (2007).
32. Xiong, W. et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol. 80, 27-37 (2006)
33. Terashima, T., Oka, K., Kritz, A.B., Kojima, H., Baker, A.H. & Chan, L. DRg-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest. 119, 2100-2112 (2009).
34. Brunetti-Pierri, N. et al. sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum. Gene Ther. 16, 811-820 (2005).
35. McCormack, W.M. Jr et al. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J. Thromb. Haemost. 4, 1218-1225 (2006)
36. Lamartina, S. et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efcacy. J. Gene Med. 9, 862-874 (2007).
37. Kiang, A. et al. Fully deleted adenovirus persistently expressing gAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant gsD-II mice. Mol. Ther. 13, 127-134 (2006).
38. Oka, K. et al. sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther. 14, 191-202 (2007).
39. Schillinger, K.J. et al. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc. Natl. Acad. Sci. U.S.A. 102, 13789-13794 (2005)
40. Thomas, C.E., schiedner, G., Kochanek, S., Castro, M.G. & Lowenstein, P.R. Preexisting antiadenoviral immunity is not a barrier to efcient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 12, 839-846 (2001).
41. Matthews, K. et al. Identifying the safety profle of Ad5.sstR/tK.RgD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin. Cancer Res. 15, 4131-4137 (2009).
42. Langford, G., Dayan, A., Yla-Herttuala, S. & Eckland, D. A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J. Gene Med. 11, 468-476 (2009).
43. Sonabend, A.M. et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of syrian hamsters and cotton rats. Cancer Gene Ther. 16, 362-372 (2009)
44. Ali, S. et al. Infammatory and anti-glioma efects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 10, 1071-1084 (2004).
45. Dewey, R.A. et al. Chronic brain infammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. 5, 1256-1263 (1999).
46. Candolf, M. et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol. 85, 133-148 (2007).
47. Puntel, M. et al. Quantifcation of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative taqMan real-time polymerase chain reaction. Hum. Gene Ther. 17, 531-544 (2006).